Invitae (NYSE:NVTA) Trading 7.8% Higher
Invitae (NYSE:NVTA) Trading 7.8% Higher
Invitae Co. (NYSE:NVTA – Get Rating)'s share price traded up 7.8% on Wednesday . The company traded as high as $2.78 and last traded at $2.77. 23,439 shares changed hands during trading, a decline of 100% from the average session volume of 11,116,942 shares. The stock had previously closed at $2.57.
週三，Invitae Co.(紐約證券交易所代碼：NVTA-GET Rating)股價上漲7.8%。該公司股價最高漲至2.78美元，最新報2.77美元。23,439股股票在交易中易手，較11,116,942股的平均成交量下跌100%。該股此前收盤報2.57美元。
Analyst Ratings Changes
分析師評級發生變化
A number of research analysts have weighed in on the company. Cowen increased their price target on Invitae to $2.80 in a research note on Tuesday, November 15th. SVB Leerink increased their target price on Invitae from $2.50 to $3.00 and gave the stock a "market perform" rating in a research report on Wednesday, November 9th. Credit Suisse Group started coverage on Invitae in a research report on Wednesday, August 24th. They issued an "underperform" rating on the stock. JPMorgan Chase & Co. lowered Invitae from a "neutral" rating to an "underweight" rating in a research report on Wednesday, August 10th. Finally, William Blair reaffirmed a "market perform" rating on shares of Invitae in a research report on Tuesday, November 8th. Four equities research analysts have rated the stock with a sell rating and nine have given a hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $8.04.
許多研究分析師都對該公司發表了看法。考恩在11月15日星期二的一份研究報告中將Invitae的目標價上調至2.80美元。SVB Leerink在11月9日(週三)的一份研究報告中將Invitae的目標價從2.50美元上調至3.00美元，並給予該股“市場表現”評級。瑞士信貸集團在8月24日星期三的一份研究報告中開始對Invitae進行報道。他們對該股給予了“表現不佳”的評級。摩根大通公司在8月10日星期三的一份研究報告中將Invitae的評級從中性下調至減持。最後，威廉·布萊爾在11月8日星期二的一份研究報告中重申了對Invitae股票的“市場表現”評級。4名股票研究分析師對該股的評級為賣出，9名分析師對該股的評級為持有。根據MarketBeat的數據，該股的普遍評級為持有，平均目標價為8.04美元。
Invitae Price Performance
Invitae性價比
The firm has a 50 day moving average price of $2.58 and a two-hundred day moving average price of $2.93. The company has a debt-to-equity ratio of 10.03, a quick ratio of 6.18 and a current ratio of 6.44.
該公司的50日移動均線價格為2.58美元，200日移動均線價格為2.93美元。該公司的負債權益比率為10.03，速動比率為6.18，流動比率為6.44。
Institutional Trading of Invitae
Invitae的制度性交易
Several large investors have recently modified their holdings of the business. Arizona State Retirement System grew its stake in shares of Invitae by 4.6% during the first quarter. Arizona State Retirement System now owns 55,072 shares of the medical research company's stock valued at $439,000 after acquiring an additional 2,425 shares in the last quarter. Mackenzie Financial Corp grew its stake in Invitae by 25.1% in the second quarter. Mackenzie Financial Corp now owns 13,948 shares of the medical research company's stock worth $34,000 after purchasing an additional 2,795 shares in the last quarter. Private Advisor Group LLC grew its stake in Invitae by 9.7% in the first quarter. Private Advisor Group LLC now owns 32,282 shares of the medical research company's stock worth $258,000 after purchasing an additional 2,845 shares in the last quarter. SG Americas Securities LLC grew its stake in Invitae by 42.1% in the first quarter. SG Americas Securities LLC now owns 10,341 shares of the medical research company's stock worth $82,000 after purchasing an additional 3,062 shares in the last quarter. Finally, Envestnet Asset Management Inc. grew its stake in Invitae by 5.1% in the first quarter. Envestnet Asset Management Inc. now owns 63,738 shares of the medical research company's stock worth $508,000 after purchasing an additional 3,096 shares in the last quarter. 88.27% of the stock is currently owned by institutional investors and hedge funds.
幾家大型投資者最近調整了對該公司的持股。亞利桑那州立退休系統第一季度在Invitae的持股增加了4.6%。亞利桑那州退休系統現在擁有55,072股這家醫學研究公司的股票，價值439,000美元，在上個季度額外購買了2,425股。麥肯齊金融公司第二季度在Invitae的持股增加了25.1%。麥肯錫金融公司(Mackenzie Financial Corp)目前持有這家醫療研究公司13,948股股票，價值34,000美元，上一季度又購買了2,795股。Private Advisor Group LLC在第一季度增持了Invitae 9.7%的股份。Private Advisor Group LLC現在持有這家醫療研究公司32,282股股票，價值258,000美元，上個季度又購買了2,845股。第一季度，SG America Securities LLC在Invitae的持股增加了42.1%。SG America Securities LLC現在持有這家醫療研究公司10,341股股票，價值82,000美元，上個季度又購買了3,062股。最後，Envestnet Asset Management Inc.在第一季度增持了Invitae 5.1%的股份。Envestnet Asset Management Inc.現在持有這家醫療研究公司63,738股股票，價值508,000美元，上個季度又購買了3,096股。88.27%的股票目前由機構投資者和對衝基金持有。
About Invitae
關於Invitae
(Get Rating)
(獲取評級)
Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services.
Invitae公司是一家醫學遺傳學公司，將遺傳信息整合到主流醫學中，以改善美國、加拿大和國際上人們的醫療保健。該公司提供各種臨牀領域的基因測試，包括遺傳癌、心臟病學、神經病學、兒科、腫瘤學、代謝疾病和罕見疾病；數字健康解決方案；以及健康數據服務。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Invitae (NVTA)
- Institutional Support for Analog Devices Remains High
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Microsoft Shares: Is it Time to Back Up the Truck?
- Is the 60/40 Portfolio Mix Still in Vogue?
- Three CBD Stocks to Dominate a Budding Industry
- 免費獲取StockNews.com關於Invitae的研究報告(NVTA)
- 機構對ADI的支持仍然很高
- Salesforce裁員，儘管面臨挑戰，但收入強勁
- 微軟股票：是時候備份卡車了嗎？
- 60/40的投資組合組合還在《時尚》雜誌上流行嗎？
- 三隻CBD股票將主宰一個萌芽行業
Receive News & Ratings for Invitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invitae and related companies with MarketBeat.com's FREE daily email newsletter.
接受《邀請日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Invitae和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。